Prometheus Biosciences, Inc. (NASDAQ:RXDX) Receives Consensus Rating of “Hold” from Brokerages

Prometheus Biosciences, Inc. (NASDAQ:RXDX – Get Rating) has received an average rating of “Hold” from the eleven research firms that are currently covering the firm, Marketbeat.com reports. Seven analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $162.14.

RXDX has been the subject of a number of analyst reports. Royal Bank of Canada lowered Prometheus Biosciences from an “outperform” rating to a “sector perform” rating in a research report on Tuesday, April 18th. Oppenheimer upped their price target on Prometheus Biosciences from $125.00 to $150.00 and gave the stock an “outperform” rating in a research note on Wednesday, March 1st. Stifel Nicolaus cut Prometheus Biosciences from a “buy” rating to a “hold” rating and increased their target price for the stock from $155.00 to $200.00 in a research note on Sunday, April 16th. The Goldman Sachs Group upped their price target on Prometheus Biosciences from $117.00 to $144.00 and gave the company a “buy” rating in a report on Tuesday, January 31st. Finally, Wells Fargo & Company downgraded Prometheus Biosciences from an “overweight” rating to an “equal weight” rating in a report on Tuesday, April 18th.

Insider Buying and Selling

In other Prometheus Biosciences news, CFO Keith W. Marshall sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 5th. The stock was sold at an average price of $108.42, for a total transaction of $1,084,200.00. Following the completion of the transaction, the chief financial officer now owns 9,811 shares in the company, valued at approximately $1,063,708.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Prometheus Biosciences news, CEO Mark C. Mckenna sold 700 shares of the firm’s stock in a transaction that occurred on Wednesday, March 1st. The stock was sold at an average price of $125.26, for a total transaction of $87,682.00. Following the completion of the transaction, the chief executive officer now owns 55,144 shares in the company, valued at approximately $6,907,337.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Keith W. Marshall sold 10,000 shares of Prometheus Biosciences stock in a transaction that occurred on Wednesday, April 5th. The stock was sold at an average price of $108.42, for a total value of $1,084,200.00. Following the completion of the transaction, the chief financial officer now owns 9,811 shares of the company’s stock, valued at approximately $1,063,708.62. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 921,320 shares of company stock worth $105,745,913. 13.08% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Prometheus Biosciences

Institutional investors and hedge funds have recently modified their holdings of the stock. Clearstead Advisors LLC purchased a new position in shares of Prometheus Biosciences in the 1st quarter worth approximately $39,000. Assetmark Inc. purchased a new position in shares of Prometheus Biosciences in the 1st quarter worth approximately $41,000. Sandia Investment Management LP purchased a new position in shares of Prometheus Biosciences in the 4th quarter worth approximately $55,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Prometheus Biosciences by 51.2% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 644 shares of the biopharmaceutical company’s stock worth $69,000 after acquiring an additional 218 shares during the last quarter. Finally, Money Concepts Capital Corp bought a new stake in shares of Prometheus Biosciences during the 4th quarter worth approximately $71,000. Hedge funds and other institutional investors own 78.31% of the company’s stock.

Prometheus Biosciences Stock Performance

NASDAQ:RXDX opened at $192.50 on Monday. The stock has a market cap of $9.20 billion, a P/E ratio of -54.69 and a beta of -0.50. The company has a current ratio of 37.56, a quick ratio of 37.56 and a debt-to-equity ratio of 0.04. The stock’s 50-day moving average is $152.91 and its 200-day moving average is $116.16. Prometheus Biosciences has a 1-year low of $22.31 and a 1-year high of $197.83.

Prometheus Biosciences (NASDAQ:RXDX – Get Rating) last announced its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.86) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.06. Prometheus Biosciences had a negative return on equity of 33.50% and a negative net margin of 3,768.76%. The business had revenue of $1.11 million for the quarter, compared to analysts’ expectations of $0.46 million. The firm’s revenue was down 71.8% compared to the same quarter last year. Equities research analysts anticipate that Prometheus Biosciences will post -3.84 earnings per share for the current year.

Prometheus Biosciences Company Profile

(Get Rating)

Prometheus Biosciences, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease.